文献速递消化道肿瘤放疗胸部肿瘤放疗

食管癌三模式治疗中放射性心脏毒性的剂量学预测因素:多中心分析

A Multi-Institutional Analysis of Radiation Dosimetric Predictors of Toxicity After Trimodality Therapy for Esophageal Cancer.
PubMed 文献 · Pract Radiat Oncol · 2021-01-21

该多中心回顾性研究分析了465例接受放化疗后手术的食管癌患者,探讨心脏和肺的剂量体积直方图参数与心肺毒性及生存的关系。单因素分析显示心脏V20Gy、V30Gy、V40Gy与心脏毒性风险增加相关,多因素分析中心脏V30Gy与不良事件独立相关。心脏V30Gy为14%、20%、30%时,心脏毒性风险分别为5%、10%、15%;V30Gy每增加10%,心脏毒性相对风险增加24%。

要点

  • 心脏V30Gy为14%、20%、30%时,心脏毒性风险分别为5%、10%、15%。
  • 未发现肺DVH指标与肺毒性相关。

核心结论

  • 食管癌三模式治疗中,心脏剂量与心脏毒性存在关联,心脏V30Gy是独立预测因素。

研究设计与样本

  • 多中心回顾性队列研究,纳入2007至2013年间2家三级医院连续465例接受放化疗后手术的食管癌患者。
  • 采用逻辑回归分析肺和心脏DVH参数与心肺毒性及生存的关联,并将显著变量纳入多因素模型,校正年龄、吸烟史、既往心脏病史和化疗类型。

主要发现

  • 患者中位年龄61岁(四分位距54-68岁),86%为男性;60%有已知心脏危险因素,64%为当前或既往吸烟者,10%有其他肺部合并症。
  • 96%为II至III期,94%为腺癌,多数位于远端食管;放疗方式包括三维适形RT(38%)、调强RT(41%)和质子治疗(20%)。
  • 未发现肺DVH指标与肺毒性相关。

关键数值与推荐

  • 心脏V30Gy为14%时心脏毒性风险为5%,为20%时为10%,为30%时为15%。
  • 心脏V30Gy每增加10%,心脏毒性相对风险增加24%。

临床怎么用

  • 在食管癌三模式治疗放疗计划评估中,应关注心脏V30Gy等剂量学参数,以评估心脏毒性风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This multi-institutional review explored associations between radiation dose-volume histogram (DVH) parameters and cardiopulmonary toxicities with trimodality therapy for esophageal cancer. METHODS AND MATERIALS: We reviewed 465 consecutive patients with esophageal cancer treated with chemoradiation therapy followed by surgery at 2 tertiary-care institutions between 2007 and 2013. Using logistic regression, we assessed associations between lung and heart DVH parameters and cardiopulmonary toxicities and survival. Statistically significant variables were subsequently included in multivariable models, which incorporated age, smoking history, previous history of heart disease, and type of chemotherapy. RESULTS: The median age of the patients was 61 years (interquartile range, 54-68 years), and 86% were men. At baseline, 60% of the patients had known cardiac risk factors, 64% were current or former smokers, and 10% had other pulmonary comorbidities. Most patients had stage II to III (96%) adenocarcinoma (94%) of the distal esophagus. The radiation therapy (RT) modalities used were 3-dimensional conformal RT (38%), intensity modulated RT (41%), and proton therapy (20%). An increased heart dose was associated with increased risk of cardiac toxicity on univariable analysis (V20 Gy: odds ratio [OR], 1.20; 95% CI, 1.08-1.33; P = .001) (V30 Gy: OR, 1.24; 95% CI, 1.11-1.38; P < .0001) (V40 Gy: OR, 1.18; 95% CI, 1.03-1.35; P = .018). No lung DVH metrics were associated with lung toxicity. Heart V30 Gy was associated with adverse events on multivariable analysis (OR, 1.15; 95% CI, 1.04-1.26; P = .0047). CONCLUSIONS: We observed an association between heart dose and cardiac toxicity for esophageal cancer. The risk of cardiac toxicity was 5%, 10%, and 15% when the heart V30 Gy dose was 14%, 20%, and 30%, respectively. For every 10% increase in V30 Gy, there was a corresponding 24% increase in the relative risk of cardiac toxicity.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Garant A, Spears G, Routman D, et al. A Multi-Institutional Analysis of Radiation Dosimetric Predictors of Toxicity After Trimodality Therapy for Esophageal Cancer. Pract Radiat Oncol. 2021. PMID: 33486102. doi:10.1016/j.prro.2021.01.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。